LENTI

DEAD

Serial Number

79213045

Owner

bluebird bio, Inc.

Filing Date

Feb 20, 2017

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

LENTI Trademark

Serial Number: 79213045

LENTI is a trademark filed by bluebird bio, Inc. on February 20, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Owner Contact Info

bluebird bio, Inc. (77 trademarks)

455 Grand Union Blvd

Entity Type: 03

Bluebird Bio (UK) Ltd. (46 trademarks)

Belvedere House,

Entity Type: 99

Genetix Biotherapeutics Inc. (63 trademarks)

455 Grand Union Boulevard
Somerville, MA 02145

Entity Type: 03

Legal Representation

Correspondence Address

John L. DuPre' Hamilton, Brook, Smith & Reynolds, P.C.

530 Virginia Road, P.O. Box 9133

Concord, MA 01742-9133

UNITED STATES

Trademark Details

Filing Date

February 20, 2017

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations and substances for the treatment of genetic diseases, immunological diseases and cancer

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB

Dec 18, 2025 ADCH

NEW REPRESENTATIVE AT IB RECEIVED

Nov 13, 2025 NREP

NEW REPRESENTATIVE AT IB RECEIVED

Sep 13, 2024 NREP

NEW REPRESENTATIVE AT IB RECEIVED

Jun 15, 2024 NREP

CHANGE OF NAME/ADDRESS REC'D FROM IB

Dec 23, 2023 ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

Aug 26, 2022 ADCH

FINAL DECISION TRANSACTION PROCESSED BY IB

Dec 20, 2019 FINT

FINAL DISPOSITION NOTICE SENT TO IB

Dec 2, 2019 FICS

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

Nov 30, 2019 FICR

NEW REPRESENTATIVE AT IB RECEIVED

Nov 15, 2019 NREP

NEW REPRESENTATIVE AT IB RECEIVED

Oct 18, 2019 NREP

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

Jan 17, 2019 OPNX

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

Jan 2, 2019 OPNS

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

Jan 2, 2019 OPNR

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND

Nov 30, 2018 MAB2

ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE

Nov 30, 2018 ABN2

CHANGE OF OWNER RECEIVED FROM IB

Nov 8, 2018 CHLD

NOTIFICATION OF FINAL REFUSAL EMAILED

May 4, 2018 GNFN

FINAL REFUSAL E-MAILED

May 4, 2018 GNFR

FINAL REFUSAL WRITTEN

May 4, 2018 CNFR

TEAS/EMAIL CORRESPONDENCE ENTERED

Apr 13, 2018 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Apr 12, 2018 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Apr 12, 2018 TROA

REFUSAL PROCESSED BY IB

Nov 17, 2017 RFNT

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Oct 13, 2017 GNRN

NON-FINAL ACTION E-MAILED

Oct 13, 2017 GNRT

NON-FINAL ACTION WRITTEN

Oct 13, 2017 CNRT

NEW REPRESENTATIVE AT IB RECEIVED

Sep 28, 2017 NREP

TEAS/EMAIL CORRESPONDENCE ENTERED

Sep 23, 2017 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Sep 22, 2017 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Sep 22, 2017 TROA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Sep 21, 2017 ARAA

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

Sep 21, 2017 REAP

NEW REPRESENTATIVE AT IB RECEIVED

Aug 25, 2017 NREP

REFUSAL PROCESSED BY IB

Aug 18, 2017 RFNT

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

Aug 2, 2017 RFCS

REFUSAL PROCESSED BY MPU

Aug 2, 2017 RFRR

APPLICATION FILING RECEIPT MAILED

Aug 1, 2017 MAFR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

Jul 29, 2017 RFCR

NON-FINAL ACTION WRITTEN

Jul 28, 2017 CNRT

ASSIGNED TO EXAMINER

Jul 28, 2017 DOCK

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Jul 28, 2017 NWOS

SN ASSIGNED FOR SECT 66A APPL FROM IB

Jul 27, 2017 REPR

Related Trademarks

More from this Owner

G GENETIX BIOTHERAPEUTICS

GENETIX BIOTHERAPEUTICS

ZYNTEGLO

More in Same Class

NOVOSTIM

SUPREME HEALTH